Experimental Therapy of Advanced Breast Cancer: Targeting NFAT1-MDM2-p53 Pathway.

Abstract

Advanced breast cancer, especially advanced triple-negative breast cancer, is typically more aggressive and more difficult to treat than other breast cancer phenotypes. There is currently no curable option for breast cancer patients with advanced diseases, highlighting the urgent need for novel treatment strategies. We have recently discovered that the nuclear factor of activated T cells 1 (NFAT1) activates the murine double minute 2 (MDM2) oncogene. Both MDM2 and NFAT1 are overexpressed and constitutively activated in breast cancer, particularly in advanced breast cancer, and contribute to its initiation, progression, and metastasis. MDM2 regulates cancer cell proliferation, cell cycle progression, apoptosis, migration, and invasion through both p53-dependent and -independent mechanisms. We have proposed to target the NFAT1-MDM2-p53 pathway for the treatment of human cancers, especially breast cancer. We have recently identified NFAT1 and MDM2 dual inhibitors that have shown excellent in vitro and in vivo activities against breast cancer, including triple-negative breast cancer. Herein, we summarize recent advances made in the understanding of the oncogenic functions of MDM2 and NFAT1 in breast cancer, as well as current targeting strategies and representative inhibitors. We also propose several strategies for inhibiting the NFAT1-MDM2-p53 pathway, which could be useful for developing more specific and effective inhibitors for breast cancer therapy.

• Authors: Jiang-Jiang Qin, Wei Wang, Ruiwen Zhang
• Journal: Progress in molecular biology and translational science (Prog Mol Biol Transl Sci) Vol. 151 Pg. 195-216 ( 2017) ISSN: 1878-0814 [Electronic] Netherlands
• PMID: 29096894 (Publication Type: Journal Article, Review, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2017. Published by Elsevier Inc.

Chemical References

• NFATC Transcription Factors
• Tumor Suppressor Protein p53
• Proto-Oncogene Proteins c-mdm2

Topics

• Breast Neoplasms (drug therapy, metabolism, pathology)
• Female
• Humans
• Molecular Targeted Therapy
• NFATC Transcription Factors (metabolism)
• Neoplasm Staging
• Proto-Oncogene Proteins c-mdm2 (metabolism)
• Signal Transduction
• Tumor Suppressor Protein p53 (metabolism)